VENLO, The Netherlands, June 23, 2016 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QIAGEN N.V. has in total received acceptances from shareholders in Exiqon A/S representing 34,852,938 shares or approximately 94.52% of the share capital and voting rights in Exiqon A/S. The Offer will be settled in cash through the shareholders in Exiqon's own custodian banks and will be effected as soon as possible, but not later than 28 June 2016. QIAGEN N.V. will apply for a delisting of the shares of Exiqon A/S and intends to initiate a squeeze-out of the remaining minority shareholders immediately after completion of the offer.
"We are very pleased to have completed this transaction and will now initiate the integration process", commented Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "We welcome our new employees to the QIAGEN family and look forward to providing the exciting benefits of the now combined portfolio to research and diagnostic laboratories."
Exiqon has a strong position in the promising new market of non-coding RNA (ncRNA). The company has developed and successfully commercialized comprehensive RNA technology solutions that fit seamlessly into QIAGEN's Sample to Insight portfolio. Together with Exiqon, QIAGEN expects to deliver a broad and industry leading offering of molecular biology solutions - spanning sample technologies, assay technologies, and bioinformatics.
Click here for full press release
SOURCE QIAGEN N.V.